An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Celanese Announces Agreement with Glaukos Corporation for Sustained Release Glaucoma Treatment
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Celanese (NYSE: CE) has announced a partnership with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for the iDose® TR intraocular implant. This device aims to lower intraocular pressure in patients with glaucoma by providing continuous, long-duration therapy, addressing issues of patient non-adherence to topical medications. Glaukos submitted a New Drug Application for iDose TR in February 2023, pending FDA approval. The collaboration is aimed at enhancing patient treatment options in ophthalmology, leveraging the proven performance of Celanese's VitalDose technology, which has a solid history of controlled-release applications.
Positive
Partnership with Glaukos may expand market presence in ophthalmology.
Potential for continuous drug delivery could enhance patient adherence and health outcomes.
Negative
FDA approval for iDose TR is still pending, introducing regulatory uncertainty.
Celanese to Supply VitalDose® Drug Delivery Platform for Glaukos’ Investigational iDose® TR Intraocular Implant
DALLAS--(BUSINESS WIRE)--
Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, today announced that it has entered into an agreement with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR, a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. iDose TR is designed to address patient non-adherence and chronic side effects associated with topical medications by providing 24/7, long-duration therapy. Glaukos submitted a New Drug Application to the U.S. Food and Drug Administration for iDose TR in February 2023, which has not yet been approved.
Sustained delivery of therapeutics has become an increasingly important approach to treating glaucoma. With the VitalDose® Drug Delivery Platform, there is now the potential to provide continuous dosing which can reduce patient compliance and adherence issues.
“The inclusion of our VitalDose® Platform in Glaukos’ iDose TR therapy furthers our mission to improve patient health in ophthalmology for those living with chronic eye diseases,” says Cyonna Holmes, global business strategy leader for ophthalmology at Celanese. “Our team is excited to support Glaukos as they continue to advance their efforts to bring iDose TR to patients who may need a new glaucoma treatment alternative.”
The VitalDose® Drug Delivery Platform provides reliable, controlled-release performance and has a long history of use in approved parenteral drug products in the United States and Europe. For more information on Celanese VitalDose technology, visit www.vitaldose.com.
About Celanese
Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 13,000 employees worldwide and had 2022 net sales of $9.7 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com.
What is the purpose of the VitalDose Drug Delivery Platform?
The VitalDose platform is designed to provide continuous dosing for patients with glaucoma, improving adherence to treatment.
When did Glaukos submit the New Drug Application for iDose TR?
Glaukos submitted the New Drug Application for iDose TR in February 2023.
How does the partnership with Glaukos impact Celanese’s business?
The partnership may enhance Celanese's presence in the ophthalmology market by integrating its drug delivery technology into Glaukos' glaucoma treatments.
What type of patients is the iDose TR implant designed for?
iDose TR is designed for patients suffering from primary open-angle glaucoma or ocular hypertension.
What are the expected benefits of the iDose TR implant?
The implant aims to lower intraocular pressure while addressing patient non-adherence to topical medications.
